摘要
目的检测前列腺癌(PCa)患者前列腺液中DD3基因的表达,讨论其临床意义。方法收集31例PCa患者、59例前列腺增生(BPH)患者前列腺液,离心取细胞沉淀物,提取总RNA,采用逆转录-聚合酶链反应(RT-PCR)琼脂糖电泳法方法检测其中DD3 mRNA的水平。同时用2χ检验分析比较不同Gleason分级的PCa患者DD3 mRNA阳性率是否存在差异。结果 PCa患者前列腺液中DD3 mRNA阳性率(77.42%)明显高于BPH患者(5.08%),两者具有显著性差异(P<0.01)。DD3 mRNA表达阳性率诊断PCa的灵敏度为77.42%,特异度为94.91%,不同Gleason分级的PCa患者DD3 mRNA表达阳性率无显著统计学差异(P>0.05)。结论检测前列腺液中DD3 mRNA诊断PCa是一种有效的无侵入性的良好方法。
Objective To detect the differential display code 3 mRNA（DD3 mRNA） in the prostatic fluid sample of patients with prostate cancer and to evaluate its clinical significance.Methods The prostatic fluid samples were collected from 31 patients with prostate cancer and 59 patients with benign prostatic hyperplasia.The total RNA had been extracted from cells of prostatic fluid for RT-Polymerase chain reaction,and agarose gel electrophoresis was applied to confirm PCR product.The difference between Gleason grade and DD3 mRNA positive rate was analyzed by χ2 test.Results There was significant difference of DD3 mRNA positive rate in prostatic fluid sediment between PCa（77.42%） and BPH（5.08%） patients（P0.01）.The sensitivity and specificity for DD3 mRNA positive rate were 77.42% and 94.91%.DD3 mRNA positive rate had no significant difference between different Gleason grade（P0.05）.Conclusion Detection of DD3 mRNA in prostatic fluid has excellent diagnostic significance for prostate cancer as a promising non-invasive method.
出处
《现代泌尿外科杂志》
CAS
2010年第6期429-432,共4页
Journal of Modern Urology
基金
西安市科技发展引导计划资助项目(No.SF08006)
